Form 4: Phibro CEO Jack Bendheim Executes Stock Sale Plan

Phibro Animal Health Corporation CEO Jack Bendheim and BFI Co., LLC sold a total of 21,117 shares of Class A Common Stock via a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO of Phibro Animal Health Corporation, reported the sale of 21,117 shares of Class A Common Stock.
• The transactions occurred between April 28, 2026, and April 30, 2026.
• Sales were executed by BFI Co., LLC, an entity over which Mr. Bendheim exercises voting and dispositive power.
• The sales were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 11, 2025.
• The shares were sold at weighted average prices ranging from $52.6473 to $56.6896 per share.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sales were pre-planned and do not necessarily reflect a change in the CEO's outlook on the company's fundamental performance.

Positives

• The sales were executed under a pre-established Rule 10b5-1 trading plan, which is a standard mechanism for insiders to sell stock without triggering concerns regarding non-public information.

Negatives

• The sale represents a reduction in the beneficial ownership stake held by the CEO and his associated entity.

Risks

• Continued divestment by major shareholders or insiders could potentially impact market sentiment regarding the stock.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that insider selling via 10b5-1 plans is a routine corporate governance practice, typically used to provide liquidity for executives and avoid the appearance of trading on material non-public information.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for executives at publicly traded companies like Zoetis or Elanco to manage equity holdings.

Related Party Transactions

• The filing discloses that Jack Bendheim exercises voting and dispositive power over BFI Co., LLC, which holds the shares.

Stakeholder Impact

• Shareholders should note the reduction in insider holdings, though the systematic nature of the 10b5-1 plan mitigates concerns of opportunistic selling.

Next Steps

• Continued monitoring of future Form 4 filings for further insider activity.

Key Dates

Keywords

Phibro Animal Health, PAHC, Insider Trading, Form 4, Jack Bendheim, 10b5-1 Plan